Benoit Arsenault (Canada)

Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec Cardiology
Dr. Benoit Arsenault obtained his Ph.D. in Physiology-Endocrinology from Université Laval in Québec City, Canada in 2009. After two postdoctoral fellowships at the Academic Medical Center in Amsterdam and at the Montreal Heart Institute, Dr. Arsenault joined the Department of Medicine of Université Laval in 2013. He is also a research scientist in the cardiology axis at the Québec Heart and Lung Institute. Dr. Arsenault’s team use genetic tools such as Mendelian randomization and family studies to investigate the causes and consequences of cardiometabolic diseases such as non-alcoholic fatty liver disease, dyslipidemia, type 2 diabetes and cardiovascular diseases. He also leads a research program funded by the Canadian Institutes of Health Research on the basic and genetic mechanisms through which Lipoprotein(a) contributes to heart valve disorders such as calcific aortic valve stenosis using multi-omic technologies. Dr. Arsenault holds a junior scholar award from the Fonds de recherche du Québec: Santé (FRQS) and his research is also funded by the Foundation of the Québec Heart and Lung Institute. Dr. Arsenault is a member of the International Chair on Cardiometabolic Risk (ICCR), the Lipoprotein(a) Foundation Scientific Advisory Board and the Genomic Investigation of Statin Therapy (GIST) and the GENIUS-CHD consortia. He has authored or co-authored more than 130 peer-reviewed manuscripts. He is also on the Editorial board and serves as social media curator for American Journal of Physiology – Endocrinology and Metabolism.

Author Of 2 Presentations

Lifestyle and prevention: how do we define success? (ID 1313)

Session Type
Advanced Clinical Seminars
Session Time
14:00 - 15:00
Date
Wed, 02.06.2021
Room
Live Streamed
Lecture Time
14:18 - 14:33

O061 - Lipoprotein(a) is not associated with active calcification assessed with 18F-NaF PET/CT in patients with mild to moderate aortic valve stenosis (ID 1450)

Session Type
Late Breaking Sessions
Session Time
10:00 - 11:15
Date
Wed, 02.06.2021
Room
Hall A (Live Q&A)
Lecture Time
10:21 - 10:28

Abstract

Background and Aims

Lipoprotein [Lp(a)] has emerged as a causal risk factor for aortic valve stenosis (AVS). 18F-NaF is a surrogate marker for active calcification and disease progression. We hypothesized that AVS patients with elevated Lp(a) levels are characterized by increased valvular 18F-NaF-uptake.

Methods

We performed 18F-NaF PET/CT in patients with mild to moderate AVS, and high versus low Lp(a) levels (> versus <50 mg/dl, respectively). Subjects were matched according to age, gender, peak aortic jet velocity, and valve morphology. We used a target-to-background ratio (TBR) with a most diseased segment (MDS) approach to compare 18F-NaF-uptake between groups.

Results

A total of 52 individuals were included in the analysis. Mean age was 66.4±5.5 years, 44 (84.6%) were men, and mean aortic valve velocity was 2.80±0.49 m/s. Median Lp(a) was 79 [64-117] and 7 [5-11] mg/dL in the high and low Lp(a) group, respectively. Systolic blood pressure and LDL-C (corrected for Lp(a)) were significantly higher in the low Lp(a) group (141±12 vs 128±12 mmHg, 2.5±1.1 vs 1.9±0.8 mmol/L). We found no difference in valvular 18F-NaF-uptake between high and low Lp(a) groups (3.02±1.26 vs 3.05±0.96, p=0.902). Linear regression analysis showed valvular calcium score to be the only significant determinant of valvular 18F-NaF-uptake (β=0.63; 95%CI:0.38-0.88 per 1,000 AU increase, p<0.001). Lp(a) was not significantly associated with 18F-NaF uptake (β=0.17; 95%CI:-0.44;0.88, p=0.305 for the high Lp(a) group).

Conclusions

Among patients with mild to moderate AVS, active calcification is predominantly determined by established calcium burden. The results do not support our hypothesis that Lp(a) is associated with valvular 18F-NaF uptake.

Hide

Presenter of 1 Presentation

Lifestyle and prevention: how do we define success? (ID 1313)

Session Type
Advanced Clinical Seminars
Session Time
14:00 - 15:00
Date
Wed, 02.06.2021
Room
Live Streamed
Lecture Time
14:18 - 14:33